Combining Immune Checkpoint and VEGFR Inhibition in Favorable-risk and Elderly Patients with Metastatic Renal Cell Carcinoma

BACKGROUND: Immune checkpoint inhibitors and VEGFR TKIs are the most commonly used medications in metastatic renal cell carcinoma. Recently, large clinical trials have shown favorable outcomes in patients treated with combined immune checkpoint plus VEGFR inhibition compared to VEGFR inhibition alon...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Genitourin Cancer
Hauptverfasser: Varkaris, Andreas, Xu, Wenxin, Davis, Roger B., Healy, Brian, McDermott, David F.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2019
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7875559/
https://ncbi.nlm.nih.gov/pubmed/32144046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2019.11.016
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge